Language:

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

Nature reviews. Drug discovery, 2017-03, Vol.16 (3), p.203-222 [Peer Reviewed Journal]

COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Mar 2017 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2016.246 ;PMID: 28209991

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Author: Rupaimoole, Rajesha ; Slack, Frank J
Subjects: Animals ; Clinical Trials as Topic - methods ; Disease Management ; Disease susceptibility ; Genetic aspects ; Genetic regulation ; Genetic Therapy - methods ; Genetic Therapy - trends ; Health aspects ; Humans ; Innovations ; MicroRNA ; MicroRNAs - administration & dosage ; MicroRNAs - genetics ; MicroRNAs - metabolism ; Molecular targeted therapy ; Neoplasms - genetics ; Neoplasms - metabolism ; Neoplasms - therapy
Is Part Of: Nature reviews. Drug discovery, 2017-03, Vol.16 (3), p.203-222
Description: In just over two decades since the discovery of the first microRNA (miRNA), the field of miRNA biology has expanded considerably. Insights into the roles of miRNAs in development and disease, particularly in cancer, have made miRNAs attractive tools and targets for novel therapeutic approaches. Functional studies have confirmed that miRNA dysregulation is causal in many cases of cancer, with miRNAs acting as tumour suppressors or oncogenes (oncomiRs), and miRNA mimics and molecules targeted at miRNAs (antimiRs) have shown promise in preclinical development. Several miRNA-targeted therapeutics have reached clinical development, including a mimic of the tumour suppressor miRNA miR-34, which reached phase I clinical trials for treating cancer, and antimiRs targeted at miR-122, which reached phase II trials for treating hepatitis. In this article, we describe recent advances in our understanding of miRNAs in cancer and in other diseases and provide an overview of current miRNA therapeutics in the clinic. We also discuss the challenge of identifying the most efficacious therapeutic candidates and provide a perspective on achieving safe and targeted delivery of miRNA therapeutics.
Publisher: England: Nature Publishing Group
Language: English
Identifier: ISSN: 1474-1776
EISSN: 1474-1784
DOI: 10.1038/nrd.2016.246
PMID: 28209991
Source: MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Mar 2017 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2016.246 ;PMID: 28209991

Searching Remote Databases, Please Wait